October 1, 2022

reportbooth

The importance of exercise

Life sciences and health tech news roundup: AIlen Institute’s new CEO, AI2’s incubator, and more

3 min read
Allen Institute headquarters in Seattle. (Allen Institute Photo)

The legacy of the late Microsoft co-founder Paul Allen lives on at some of Seattle’s most progressive establishments.

This week GeekWire profiled the AI2 incubator, a branch of the Allen Institute for AI (AI2) launched by Allen in 2013. GeekWire co-founder Todd Bishop explored the earlier and the potential of the incubator, which is significantly fostering well being tech and biotech firms together with BirchAI and Modulus Therapeutics.

We also interviewed the new CEO of the Allen Institute, the life sciences counterpart to the AI2. Rui Costa spoke about crew exploration, his commitment to variety, and his see on the institute’s approach to new industry partnerships.

Read on for this and additional lifetime sciences and overall health tech coverage in the Pacific Northwest from GeekWire and over and above, such as a study showcasing the Allen Institute’s new visualization resource, the “Simularium Viewer.”

— Inside of the AI2 Incubator: Microsoft co-founder’s unfinished legacy fuels quest for new AI startups

The neural dynamics of teamwork: New Allen Institute CEO on diversity and effects in lifetime science

Seattle startup raises $9.7M for medical demo to exam inhaled CBD as nervousness therapy

The Allen Institute’s “Simularium Viewer” demonstrates a crimson nanoparticle about to be enveloped by a yellow lipid coat. See movie listed here. (Allen Institute Graphic)

New research:

  • The Allen Institute’s “Simularium Viewer” allows computational visualization of organic procedures and was explained in a analyze this week. Scientists showcased video simulations of a nanoparticle wrapped by an outer coat, a lung contaminated by the COVID-19 virus, and the bacterium E. Coli dividing.
  • Alpine Immune Sciences posted a preclinical analyze on its direct immuno-oncology applicant, an immune “checkpoint inhibitor” directed from 3 targets at once. The Seattle biotech enterprise is tests the compound in two medical trials.
  • Researchers at Fred Hutch and their colleagues identified that breast most cancers procedure may outcome in an elevated hazard for cardiovascular occasions. “Scientists and clinicians will have to prioritize research that will reduce this risk,” said Fred Hutch investigator Heather Greenlee in a information launch.
  • A noninvasive ultrasound strategy analyzed by University of Washington surgeon Jonathan Harper and his colleagues can dissipate kidney stones. The strategy may well guide to less invasive cure techniques and is licensed to Silicon Valley firm SonoMotion.  

Raising cash:

  • The College of Washington will establish a new tuberculosis research centre with up to $5.3 million from the U.S. Countrywide Institutes of Wellness, introduced this 7 days.
  • AVM Biotechnology landed a $1.6 million modest enterprise grant from the National Institutes of Well being. The grant will guidance preclinical study on the Seattle company’s lead compound, dependent on the corticosteroid dexamethasone. The compound triggers a specific variety of T cell and will be tested in form 1 diabetes in mouse types. In the meantime, the company is enrolling patients in a section 1/2 medical demo tests the compound in blood cancers.

Fostering startups:

  • The College of Washington Startup Job & Internship Good this year was reside and in man or woman. Biotech providers ended up entrance and centre.
  • Discover Ventures and the Washington Condition Division of Commerce selected 10 tech startups and founders for its initially “Equitable Innovations Accelerator.” Health tech firms Coltrain, Litesprite and GoldenSHERPA manufactured the slice.

Relocating up and abroad:

  • Fred Hutch investigator Phil Greenberg was elected president of the American Affiliation for Cancer Exploration.
  • Seattle biotech firm Nanostring is increasing, opening a European headquarters in Amsterdam.
  • Adaptive Biotechnologies’ former chief healthcare officer Lance Baldo has a new position with the identical title at South San Francisco-dependent Freenome.
  • Inventprise has a new CEO, Yves Leurquin, and two new board associates. The Redmond, Wash.-primarily based company also received $30 million of up to $90 million pledged by the Monthly bill & Melinda Gates Foundation to assistance clinical development of the company’s vaccine for pediatric pneumococcal sickness.

Copyright © All rights reserved. | Newsphere by AF themes.